CELG News 85.88 07/01/2014 04:35:17 Celgene Corp (CELG)
Post# of 273330
Posted On: 07/01/2014 5:35:11 AM
Celgene Corp (CELG) 85.88 $CELG
Chipotle, Keurig Near Buy Points; Energy Dominates
at Investor's Business Daily - Mon Jun 30, 6:00PM CDT
Oil and gas plays make up more than half of this week's Big Cap 20 list -- yet again. No surprises there, given high worldwide demand for fuel and the continuing turmoil in Iraq. As a result, all the energy stocks making the cut are well extended...
Final Glance: Biotechnology companies
AP - Mon Jun 30, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Gilead Sciences and Celgene Corporation Have Great Growth Potential
Selena Maranjian, The Motley Fool - Motley Fool - Mon Jun 30, 3:45PM CDT
Credit: e-Magine Art via Flickr. Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some health care and biotech stocks to your portfolio but don't have the time or expertise to...
Midday Glance: Biotechnology companies
AP - Mon Jun 30, 12:25PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Mon Jun 30, 9:33AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
CORRECTING and REPLACING Celgene Corporation Mourns the Passing of Board of Director Member, Rodman L. Drake
Business Wire - Thu Jun 26, 1:28PM CDT
Third paragraph, second sentence has been deleted because of redundancy.
Companies Chasing Gold Nugget of Immuno-Oncology Like Never Before
ACCESSWIRE - Thu Jun 26, 8:37AM CDT
WHITEFISH, MT / June 26, 2014 / Probably the most explosive field in biotechnology right now is that of immuno-oncology. The field is predicated on the concept that the body's immune system can be augmented or taught to modulate cancer without the use of toxic chemotherapy agents and radiation, the standard of care today worldwide. A few years ago, the immuno-oncology research was relatively non-existent, but now it's one of the hottest around with some big pharmas making it a primary directive. Last year, Merck & Co. (NYSE: MRK) brought back Roger Perlmutter, a man with an extensive background in immunology, for a second tour with the company, this time as EVP and President of Merck Research Laboratories, to shepherd a new path for Merck focused on oncology at the research level with an emphasis on immuno-oncology. Last week, Merck enlisted MorphoSys AG in a partnership to develop therapeutic antibodies against immune checkpoints. The antibody experts at MorphoSys are in high demand, inking development agreements with Celgene (NASDAQ: CELG), GlaxoSmithKline (NYSE: GSK), Novartis (NYSE: NVS) and more to develop antibodies to support the human immune system against cancer.
Celgene Corporation Mourns the Passing of Board of Director Member, Rodman L. Drake
Business Wire - Thu Jun 26, 7:30AM CDT
It is with great sadness that Celgene Corporation (NASDAQ:CELG) announces the death of Rodman L. Drake, a member of its Board of Directors since 2006.
'Fast Money' Recap: A Mixed Bag for Housing
at The Street - Wed Jun 25, 4:00AM CDT
The trading panel discussed the stock market's big drop, how low the S&P can go and why bonds aren't selling off.
Celgene, Chipotle, Keurig Remain In Buying Range
at Investor's Business Daily - Mon Jun 23, 6:52PM CDT
This week's Big Cap 20 list showed a few changes from last week, as Apple (AAPL), Encana (ECA) and Magna International (MGA) fell out and were replaced by Celgene (CELG), Spectra Energy (SE) and Southwest Airlines (LUV) . Energy plays still dominate...
Stocks Poised For Soft Start; Micros Systems Surges Premarket
at Investor's Business Daily - Mon Jun 23, 7:56AM CDT
The stock market today appeared poised for a mildly lower start despite upbeat Chinese factory data and a round of deal news. Nasdaq 100 futures fell 2 points vs. fair value, while S&P 500 futures edged down less than 1 point. Dow futures lost 12...
Chipotle, Keurig Near Buy Points; Energy Dominates
at Investor's Business Daily - Mon Jun 30, 6:00PM CDT
Oil and gas plays make up more than half of this week's Big Cap 20 list -- yet again. No surprises there, given high worldwide demand for fuel and the continuing turmoil in Iraq. As a result, all the energy stocks making the cut are well extended...
Final Glance: Biotechnology companies
AP - Mon Jun 30, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Gilead Sciences and Celgene Corporation Have Great Growth Potential
Selena Maranjian, The Motley Fool - Motley Fool - Mon Jun 30, 3:45PM CDT
Credit: e-Magine Art via Flickr. Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some health care and biotech stocks to your portfolio but don't have the time or expertise to...
Midday Glance: Biotechnology companies
AP - Mon Jun 30, 12:25PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Mon Jun 30, 9:33AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
CORRECTING and REPLACING Celgene Corporation Mourns the Passing of Board of Director Member, Rodman L. Drake
Business Wire - Thu Jun 26, 1:28PM CDT
Third paragraph, second sentence has been deleted because of redundancy.
Companies Chasing Gold Nugget of Immuno-Oncology Like Never Before
ACCESSWIRE - Thu Jun 26, 8:37AM CDT
WHITEFISH, MT / June 26, 2014 / Probably the most explosive field in biotechnology right now is that of immuno-oncology. The field is predicated on the concept that the body's immune system can be augmented or taught to modulate cancer without the use of toxic chemotherapy agents and radiation, the standard of care today worldwide. A few years ago, the immuno-oncology research was relatively non-existent, but now it's one of the hottest around with some big pharmas making it a primary directive. Last year, Merck & Co. (NYSE: MRK) brought back Roger Perlmutter, a man with an extensive background in immunology, for a second tour with the company, this time as EVP and President of Merck Research Laboratories, to shepherd a new path for Merck focused on oncology at the research level with an emphasis on immuno-oncology. Last week, Merck enlisted MorphoSys AG in a partnership to develop therapeutic antibodies against immune checkpoints. The antibody experts at MorphoSys are in high demand, inking development agreements with Celgene (NASDAQ: CELG), GlaxoSmithKline (NYSE: GSK), Novartis (NYSE: NVS) and more to develop antibodies to support the human immune system against cancer.
Celgene Corporation Mourns the Passing of Board of Director Member, Rodman L. Drake
Business Wire - Thu Jun 26, 7:30AM CDT
It is with great sadness that Celgene Corporation (NASDAQ:CELG) announces the death of Rodman L. Drake, a member of its Board of Directors since 2006.
'Fast Money' Recap: A Mixed Bag for Housing
at The Street - Wed Jun 25, 4:00AM CDT
The trading panel discussed the stock market's big drop, how low the S&P can go and why bonds aren't selling off.
Celgene, Chipotle, Keurig Remain In Buying Range
at Investor's Business Daily - Mon Jun 23, 6:52PM CDT
This week's Big Cap 20 list showed a few changes from last week, as Apple (AAPL), Encana (ECA) and Magna International (MGA) fell out and were replaced by Celgene (CELG), Spectra Energy (SE) and Southwest Airlines (LUV) . Energy plays still dominate...
Stocks Poised For Soft Start; Micros Systems Surges Premarket
at Investor's Business Daily - Mon Jun 23, 7:56AM CDT
The stock market today appeared poised for a mildly lower start despite upbeat Chinese factory data and a round of deal news. Nasdaq 100 futures fell 2 points vs. fair value, while S&P 500 futures edged down less than 1 point. Dow futures lost 12...
(0)
(0)